Adjuvant Global Health Technology Fund, L.P.'s Form 4 filing
AN2 Therapeutics, Inc. (ANTX) · filed Nov 16, 2023
- Accession no.
- 0000950170-23-064611
- Filed
- Nov 16, 2023, 6:59 PM ET
- Trade date
- Nov 14, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $29.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Adjuvant Global Health Technology Fund, L.P.CIK 0001783165 | 10% Owner |
| Adjuvant Global Health Technology Fund DE, L.P.CIK 0001799812 | 10% Owner |
| Adjuvant Capital Management, LLCCIK 0001935084 | 10% Owner |
| Adjuvant Capital GP, L.P.CIK 0001935100 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 14, 2023 | Common Stock | SSaleDisposed | −1,522 | $16.15 | −$24,574.21 | 2,080,051 | Direct | |
| Nov 14, 2023 | Common Stock | SSaleDisposed | −288 | $16.15 | −$4,650.05 | 393,449 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.